A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels,...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Elsevier 2022-11-01
Sraith:Journal of Lipid Research
Ábhair:
PCSK9
cardiovascular disease
hypercholesterolemia
small-molecule
lipoproteins
apolipoproteins
Rochtain ar líne:http://www.sciencedirect.com/science/article/pii/S0022227522001262

Ar líne

http://www.sciencedirect.com/science/article/pii/S0022227522001262

Míreanna comhchosúla